Phase 3 — Large-scale testing across thousands of people, comparing the new treatment against current standard treatments.
Trial locations(34 sites)
United States
Birmingham Gastroenterology Associates, Birmingham, Alabama Honor Health, Scottsdale, Arizona University of California, Irvine, Irvine, California Gastro Care Institute, Lancaster, California Cedars Sinai, Los Angeles, California San Diego Gastroenterology, San Diego, California University of Colorado Anschutz, Aurora, Colorado University of Florida, Gainesville, Florida Borland-Groover, Jacksonville, Florida Research Associates of South Florida, Miami, Florida Hillcrest Medical Research, Orange City, Florida Orlando Health, Orlando, Florida Gastroenterology Associates of Central Georgia, LLC, Macon, Georgia Rush University, Chicago, Illinois Kansas Gastroenterology, LLC, Wichita, Kansas University of Louisville, Louisville, Kentucky Tandem Clinical Research, Marrero, Louisiana Brigham and Women's Hospital, Boston, Massachusetts Washington University, St Louis, Missouri Sierra Clinical Research, Las Vegas, Nevada Rutgers University, Piscataway, New Jersey New York Presbyterian Hospital- Columbia University Medical Center, New York, New York University of North Carolina Chapel Hill, Chapel Hill, North Carolina Oregon Health and Science University, Portland, Oregon University of Pennsylvania, Philadelphia, Pennsylvania Einstein Medical Center, Philadelphia, Pennsylvania Thomas Jefferson University, Philadelphia, Pennsylvania Allegheny Health Network, Pittsburgh, Pennsylvania Vanderbilt University Medical Center, Nashville, Tennessee Baylor St. Luke's Medical Center, Houston, Texas TEN20 Clinical Research, Plano, Texas The University of Utah, Salt Lake City, Utah Swedish Medical Center, Seattle, Washington West Virginia University, Morgantown, West Virginia